# A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

> **NCT04281472** · PHASE2 · COMPLETED · sponsor: **argenx** · enrollment: 322 (actual)

## Conditions studied

- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

## Interventions

- **BIOLOGICAL:** efgartigimod PH20 SC in stage B
- **OTHER:** placebo in stage B

## Key facts

- **NCT ID:** NCT04281472
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-15
- **Primary completion:** 2023-05-11
- **Final completion:** 2023-05-11
- **Target enrollment:** 322 (ACTUAL)
- **Last updated:** 2024-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04281472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04281472, "A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04281472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*